Ethical Approval
The study was approved by the KSUMC Institutional Review Board, reference number (Ref. No. 20/0497/IRB). This study was conducted in accordance with the Declaration of Helsinki. Patient consent to review their medical records was not required by the KSUMC Institutional Review Board due to the anonymized data collection and maintained with confidentiality.
Statistical Analysis
All statistical analyses were performed using the Statistical Package for the Social Sciences software, version 22.0 (SPSS Inc., Chicago, IL, USA). Continuous variables were presented as the means ± standard deviations (SDs) and compared using one-way ANOVA to test the difference between variables and three groups of FRS. The categorical data were presented as numbers and percentages (%) and compared using the Chi-square test to determine whether there are significant differences between variables and three levels of FRS. Multiple logistic regression analysis was used to examine the associat
Israeli company Sight Diagnostic’s Sight OLO blood diagnostics device. Photo: Sight Diagnostics via Facebook.
CTech – Sight Diagnostics, an Israeli company that delivers lab-grade Full Blood Count (FBC) results in just a few minutes, has deployed its Sight OLO solution at the John Radcliffe Hospital, part of Oxford University Hospitals NHS Foundation. The deployment means that patients who attend the emergency departments have access to quick FBC testing as part of a rapid AI triage system for Covid-19.
Sight OLO helps with faster predictions to be made by CURIAL AI, a screening test developed by Oxford University that leverages the routine vital signs of patients alongside FBC results to determine the likelihood of a patient having Covid-19. The CURIAL algorithm was developed by Oxford University and has proven to be effective in ruling out the possibility of Covid-19 within patients in the first hour, as opposed to the 12-28 hour timeframe offered by Polymerase Chain Reaction
RURAL Cohort Study to Utilize PixCell Medical s HemoScreen™ Hematology Analyzer for Research Initiative
USA - English
News provided by
Share this article
Share this article
YOKNEAM ILIT, Israel, Feb. 23, 2021 /PRNewswire/ PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, announced today that the Risk Underlying Rural Areas Longitudinal Study (RURAL) has selected PixCell s novel miniaturized, portable hematology analyzer, HemoScreen™, as part of its six year research study, aiming to gain insight into the specific health-related concerns of the rural southeastern United States population. The RURAL Study is funded by the National Heart, Lung and Blood Institute (NHLBI).
Led by a group of researchers from 16 different US institutions, the RURAL study aims to understand health concerns specific to rural communities in the South, particularly related to increased rates of heart, lung, blood and sleep disorders. Focusing on ten rural counties in
Share this article
Share this article
ResearchAndMarkets.com s offering.
The Global Clinical Diagnostics Market was valued at around USD 56 billion in 2020 and is expected to grow at a steady CAGR of 8.59% during the forecast period.
The Global Clinical Diagnostics Market is driven by increasing prevalence of diseases caused due to sedentary lifestyle such as diabetes, cardiovascular diseases, high blood pressure, lipid disorders, among others. Furthermore, increase in the number of patients suffering from chronic kidney diseases and cancer is also expected to drive the market for clinical diagnostics during the forecast years. Additionally, benefits such as quick test results, easy procedure of testing, ease of procurement of samples, less pain, among others associated with clinical diagnostics are further anticipated to propel the market through 2026.